Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases

Reuters

Mar 23

<a href="https://laohu8.com/S/CABA">Cabaletta Bio</a> Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases

Cabaletta Bio outlined development of rese-cel (CABA-201), an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA submission.
The company said complete Phase 1/2 data are expected in systemic sclerosis, lupus and myasthenia gravis in 1H26.
Across the first 40 patients dosed with preconditioning, Cabaletta Bio reported 95% had no CRS or Grade 1 CRS and 95% had no ICANS.
For the RESET-Myositis registrational cohort, the presentation described a 17-patient single-arm design with a primary endpoint at Week 16 based on total improvement score off immunomodulators and on no or low-dose steroids.
The presentation said automated manufacturing using Cellares has been cleared via an IND amendment and is intended to support scalable production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621770029"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621770029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621770029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621770029","market":"us","top_or_hot":-1,"title":"Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cabaletta Bio outlined development of rese-cel (CABA-201), an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA submission.\n        </li>\n<li>\n          The company said complete Phase 1/2 data are expected in systemic sclerosis, lupus and myasthenia gravis in 1H26.\n        </li>\n<li>\n          Across the first 40 patients dosed with preconditioning, Cabaletta Bio reported 95% had no CRS or Grade 1 CRS and 95% had no ICANS.\n        </li>\n<li>\n          For the RESET-Myositis registrational cohort, the presentation described a 17-patient single-arm design with a primary endpoint at Week 16 based on total improvement score off immunomodulators and on no or low-dose steroids.\n        </li>\n<li>\n          The presentation said automated manufacturing using Cellares has been cleared via an IND amendment and is intended to support scalable production.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cabaletta Bio outlined development of rese-cel (CABA-201), an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA submission.\n        </li>\n<li>\n          The company said complete Phase 1/2 data are expected in systemic sclerosis, lupus and myasthenia gravis in 1H26.\n        </li>\n<li>\n          Across the first 40 patients dosed with preconditioning, Cabaletta Bio reported 95% had no CRS or Grade 1 CRS and 95% had no ICANS.\n        </li>\n<li>\n          For the RESET-Myositis registrational cohort, the presentation described a 17-patient single-arm design with a primary endpoint at Week 16 based on total improvement score off immunomodulators and on no or low-dose steroids.\n        </li>\n<li>\n          The presentation said automated manufacturing using Cellares has been cleared via an IND amendment and is intended to support scalable production.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLsTGy:1","article_id":"2621770029","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621770029","pubTimestamp":1774265697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cabaletta Bio outlined development of rese-cel , an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA submission.The company said complete Phase 1/2 data are expected in systemic sclerosis, lupus and myasthenia gravis in 1H26.Across the first 40 patients dosed with preconditioning, Cabaletta Bio reported 95% had no CRS or Grade 1 CRS and 95% had no ICANS.For the RESET-Myositis registrational cohort, the presentation described a 17-patient single-arm design with a primary endpoint at Week 16 based on total improvement score off immunomodulators and on no or low-dose steroids.The presentation said automated manufacturing using Cellares has been cleared via an IND amendment and is intended to support scalable production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CABA":"Cabaletta Bio"},"translate_title":"Cabaletta Bio发布用于自身免疫性疾病的Rese-cel CD19-CAR T开发公司演示文稿","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CABA":0.9},"content_text":"Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases\n    \n\n\n          Cabaletta Bio outlined development of rese-cel (CABA-201), an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA submission.\n        \n\n          The company said complete Phase 1/2 data are expected in systemic sclerosis, lupus and myasthenia gravis in 1H26.\n        \n\n          Across the first 40 patients dosed with preconditioning, Cabaletta Bio reported 95% had no CRS or Grade 1 CRS and 95% had no ICANS.\n        \n\n          For the RESET-Myositis registrational cohort, the presentation described a 17-patient single-arm design with a primary endpoint at Week 16 based on total improvement score off immunomodulators and on no or low-dose steroids.\n        \n\n          The presentation said automated manufacturing using Cellares has been cleared via an IND amendment and is intended to support scalable production.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}